Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symptoms.

Plain-language guide to PMID 28235705 (2017): crossover randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 28235705
Journal: Addictive behaviors
Year: 2017
Study type: Randomized Controlled Trial
Authors: Kotlyar M et al. (7 authors)
DOI: 10.1016/j.addbeh.2017.02.018
Registered trial: NCT01522963

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Smokers are often advised to use nicotine lozenge when craving or withdrawal symptoms occur.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

At one session, nicotine lozenge was given immediately after a stressor (to approximate current recommended use - i.e., after craving and withdrawal symptoms occur); at the other session subjects were randomized to receive nicotine lozenge at time points ranging from immediately to 30min prior to the stressor.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

Eighty-four smokers completed two laboratory sessions in random order.

Withdrawal symptoms and urge to smoke were measured using the Minnesota Nicotine Withdrawal Scale and the Questionnaire of Smoking Urges (QSU).

What Was Measured

The subject headings attached to it are Craving, Nicotine, Nicotinic Agonists, Smoking Cessation, Substance Withdrawal Syndrome, Surveys and Questionnaires and Tablets.

Author keywords: Nicotine Lozenge and Withdrawal symptoms.

What This Means in Plain Language

The paper is a randomized and crossover study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Addictive behaviors), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.